BioCentury
ARTICLE | Clinical News

Tracon reports Phase I/II data for TRC105 in HCC

September 1, 2017 6:02 PM UTC

Tracon Pharmaceuticals Inc. (NASDAQ:TCON) reported data from 24 evaluable patients with advanced hepatocellular carcinoma (HCC) in an NCI-led Phase I/II trial showing that IV TRC105 (carotuximab) every other week plus Nexavar sorafenib led to an objective response rate (ORR) of 21% over all 4 TRC105 dose levels. In 20 evaluable patients with measurable disease, the ORR was 25%. Median progression-free survival (PFS) was 3.8 months and overall survival (OS) was 15.5 months. The trial enrolled 26 patients to receive 3, 6, 10 and 15 mg/kg doses of TRC105 every other week plus Nexavar. ORR, PFS and OS were secondary endpoints, as was safety.

The maximum tolerated dose (MTD), the primary endpoint of the Phase I portion, was not established. The study was expanded at the15 mg/kg dose level. Data were published in Clinical Cancer Research...

BCIQ Company Profiles

Tracon Pharmaceuticals Inc.

BCIQ Target Profiles

Endoglin (CD105) (ENG)